Intranasal Ketamine
Transform Your
Mental Health
The first novel antidepressant in more than 30 years, SPRAVATO is an FDA-approved esketamine nasal spray for adults aged 18 years and beyond. It is used to address treatment-resistant depression (TRD) and major depressive disorder, or other conditions complicated by acute suicidality. Spravato offers the hope of immediate relief from the most severe and debilitating of depressive symptoms.
How Does SPRAVATO Work?
SPRAVATO contains esketamine, a molecule that targets NMDA receptors in the brain differently from other antidepressant medications. Administered through a nasal spray, it begins to take effect rapidly and is thought to help restore brain connections associated with mood and emotional regulation.
- Screening and Assessment: Patients undergo a comprehensive evaluation to determine their suitability for SPRAVATO therapy.
- Supervised Administration: SPRAVATO is administered in our clinic under the supervision of our healthcare professionals to monitor its effects and ensure patient safety during and after treatment.
- Monitoring: Patients are monitored for at least two hours by a healthcare provider after each administration due to potential sedation and dissociative effects and to ensure the patient’s vital signs are stable.
- Rapid Symptom Improvement: Many patients experience significant improvements in their symptoms within hours to days of the first administration, compared to traditional antidepressants that may take weeks.
- High Efficacy: SPRAVATO has been shown to reduce the symptoms of depression in a significant portion of patients who have previously not responded to other treatments.
- Well-Researched: Supported by robust clinical trials and FDA approval, ensuring it meets high safety and efficacy standards.